Arbutus Stock Performance
| ABUS Stock | USD 2.03 0.03 1.50% |
The firm shows a Beta (market volatility) of 0.2721, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Arbutus Biopharma returns are expected to increase less than the market. However, during the bear market, the loss on holding Arbutus Biopharma will be expected to be smaller as well. Even though it is essential to pay attention to Arbutus Biopharma Corp historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy in foreseeing any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Arbutus Biopharma Corp exposes fifteen different technical indicators, which can help you to evaluate its performance. Arbutus Biopharma Corp has an expected return of -0.16%. Please make sure to confirm Arbutus Biopharma Corp risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Arbutus Biopharma Corp performance from the past will be repeated at some point in the near future.
Arbutus Performance
0 of 100
Over the last 90 days Arbutus Biopharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
1 | Arbutus Biopharma Corporation Appoints Two New Executives - ... | 07/10/2023 |
2 | Acquisition by Naftzger J Christopher of 500000 shares of Ar... | 07/12/2023 |
3 | Acquisition by Rewolinski Melissa of 110000 shares of Arbutu... | 07/13/2023 |
4 | Arbutus Biopharma Q2 2023 Earnings Preview | 08/02/2023 |
5 | EPS Reported | 08/03/2023 |
6 | Vivek Ramaswamy Republican Candidates Business Career and ..... | 08/24/2023 |
7 | Small Interfering RNA Therapeutics Market is set for Rapid G... | 09/11/2023 |
| Begin Period Cash Flow | 109.3 M | |
| Total Cashflows From Investing Activities | -74.9 M |
Arbutus |
Arbutus Biopharma Relative Risk vs. Return Landscape
If you would invest 227.00 in Arbutus Biopharma Corp on July 2, 2023 and sell it today you would lose (24.00) from holding Arbutus Biopharma Corp or give up 10.57% of portfolio value over 90 days. Arbutus Biopharma Corp is currently does not generate positive expected returns and assumes 1.9093% risk (volatility on return distribution) over the 90 days horizon. In different words, 16% of stocks are less volatile than Arbutus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Arbutus Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arbutus Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Arbutus Biopharma Corp, and traders can use it to determine the average amount a Arbutus Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0819
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABUS |
Estimated Market Risk
| 1.91 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Arbutus Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arbutus Biopharma by adding Arbutus Biopharma to a well-diversified portfolio.
Arbutus Biopharma Fundamentals Growth
Arbutus Stock prices reflect investors' perceptions of the future prospects and financial health of Arbutus Biopharma, and Arbutus Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arbutus Stock performance.
| Return On Equity | -0.51 | |||
| Return On Asset | -0.24 | |||
| Current Valuation | 186.35 M | |||
| Shares Outstanding | 167.56 M | |||
| Price to Earning | (1.16) X | |||
| Price to Book | 2.81 X | |||
| Price to Sales | 11.68 X | |||
| Revenue | 39.02 M | |||
| Gross Profit | (45.39 M) | |||
| EBITDA | (61.03 M) | |||
| Net Income | (69.46 M) | |||
| Cash and Equivalents | 150.2 M | |||
| Cash per Share | 1.00 X | |||
| Total Debt | 2.19 M | |||
| Debt to Equity | 0.016 % | |||
| Current Ratio | 5.29 X | |||
| Book Value Per Share | 0.81 X | |||
| Cash Flow from Operations | (35.36 M) | |||
| Earnings Per Share | (0.48) X | |||
| Market Capitalization | 340.14 M | |||
| Total Asset | 195.42 M | |||
| Retained Earnings | (1.2 B) | |||
| Working Capital | 118.28 M | |||
| Current Asset | 183.88 M | |||
| Current Liabilities | 10.58 M | |||
About Arbutus Biopharma Performance
To evaluate Arbutus Biopharma Corp Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Arbutus Biopharma generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Arbutus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Arbutus Biopharma Corp market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Arbutus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for 2023 | ||
| Effect of Exchange Rate Changes on Cash | -22 K | -23.7 K | |
| Return on Average Assets | (0.33) | (0.35) | |
| Return on Average Equity | (0.46) | (0.50) | |
| Return on Invested Capital | (0.46) | (0.49) | |
| Return on Sales | (1.62) | (1.75) |
Things to note about Arbutus Biopharma Corp performance evaluation
Checking the ongoing alerts about Arbutus Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Arbutus Biopharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arbutus Biopharma generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 39.02 M. Net Loss for the year was (69.46 M) with loss before overhead, payroll, taxes, and interest of (45.39 M). | |
| Arbutus Biopharma Corp currently holds about 150.2 M in cash with (35.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Arbutus Biopharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 25.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Small Interfering RNA Therapeutics Market is set for Rapid Growth and Demand by 2031 - Benzinga |
- Analyzing Arbutus Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arbutus Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Arbutus Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arbutus Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arbutus Biopharma's management team can help you assess the company's leadership.
- Pay attention to analyst opinions and ratings of Arbutus Biopharma's stock. These opinions can provide insight into Arbutus Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.148 | Quarterly Revenue Growth (0.67) | Return On Assets (0.24) | Return On Equity (0.51) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.